Overview: Anti-Nuclear Antibody TestIntroduction: The Anti-Nuclear Antibody Test detects antibodies linked to autoimmune diseases like lupus, which may cause joint pain, rashes, or fatigue. Following 2023 ACR guidelines, it uses an immunoassay for high sensitivity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected systemic autoimmune conditions.
Other Names: ANA Assay, ANF Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: ANA testing began in the 1950s with immunofluorescence. Modern immunoassays emerged in the 1980s, and by the 2000s, high-sensitivity methods improved autoimmune disease detection.
Purpose: Diagnoses autoimmune diseases like lupus, guides treatment, and monitors disease activity in patients with joint pain, rashes, or fatigue.
Test Parameters: 1. Anti Nuclear Antibody
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like joint pain or rashes, and list medications like immunosuppressants.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document autoimmune symptoms, lupus history, or family history of autoimmune diseases. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for immunosuppressive therapy.
Procedural Considerations: Uses an immunoassay to measure ANA levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Immunosuppressants may suppress antibody levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive ANA results suggest lupus or other autoimmune diseases, prompting specific antibody tests. Negative results may require clinical correlation.
Specialist Consultation: Consult a rheumatologist for result interpretation. A nephrologist referral is advised for kidney involvement.
Additional Supporting Tests: Anti-ds-DNA test, complement levels, or ESR to confirm lupus or assess disease activity.
Test Limitations: False positives may occur with infections or aging. Results require clinical correlation with specific antibody tests.
References: ACR Lupus Guidelines, 2023; Arthritis and Rheumatology, Tsokos GC, 2022.
